Hepatic steatosis in participants in a program of low-dose CT screening for lung cancer

European Journal of Radiology

Volumn 94, Issue , 2017, Pages 174-179

  Chen, Xiangmeng ^a,c,d   Li, Kunwei ^a,e   Yip, Rowena ^a   Perumalswami, Ponni ^a   Branch, Andrea D ^a   Lewis, Sara ^a   Del Bello, David ^a   Becker, Betsy J ^b   Yankelevitz, David F ^a   Henschke, Claudia I ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b FLORIDA STATE UNIVERSITY   (United States)

^c THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

^d JIANGMEN CENTRAL HOSPITAL   (China)

^e THE FIFTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Computed tomography; Hepatic steatosis; Liver attenuation; Lung cancer; Screening; Smoking

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 1 ANTITRYPSIN; ASPARTATE AMINOTRANSFERASE;

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; BODY MASS; CANCER RISK; CANCER SCREENING; COMORBIDITY ASSESSMENT; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE SEVERITY; EMPHYSEMA; FATTY LIVER; FEMALE; HUMAN; INCIDENTAL FINDING; LIVER; LIVER FUNCTION TEST; LOW DOSE COMPUTER TOMOGRAPHY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIATION ATTENUATION; SEX; SPLEEN; BLOOD; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; LUNG TUMOR; PREDICTIVE VALUE; RISK FACTOR; SENSITIVITY AND SPECIFICITY; X-RAY COMPUTED TOMOGRAPHY;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; FATTY LIVER; FEMALE; HUMANS; LIVER FUNCTION TESTS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85023772172     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2017.06.024     Document Type: Article

References (27)

1. International Early Lung Cancer Action Program Protocol. http://www.ielcap.org/sites/default/files/I-ELCAP%20 protocol%202016.pdf (Accessed 23 March 2016).
2. Bedossa, P., FLIP Pathology Consortium, Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 60 (2014), 565–575.
3. Angulo, P., Kleiner, D.E., Dam-Larsen, S., et al. Liver fibrosis but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149 (2015), 389–397.
4. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO), EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64 (2016), 1388–1402.
5. Wong, V.W., Wong, G.L., Yeung, D.K., et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J. Hepatol. 62 (2015), 182–189.
6. Ma, X., Holakere, N.S., Kambadakone, R.A., et al. Imaging-based quantification of hepatic fat: methods and clinical applications. Radiographics 29 (2009), 1253–1277.
7. Davidson, L.E., Kuk, J.L., Church, T.S., et al. Protocol for measurement of liver fat by computed tomography. J. Appl. Physiol. 100 (2006), 864–868.
8. Kodama, Y., Ng, C.S., Wu, T.T., et al. Comparison of CT methods for determining the fat content of the liver. AJR Am. J. Roentgenol. 188 (2007), 1307–1312.
9. Park, S.H., Kim, P.N., Kim, K.W., et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 239 (2006), 105–112.
10. Lee, J.Y., Kim, K.M., Lee, S.G., et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J. Hepatol. 47 (2007), 239–244.
11. Sterling, R.K., Lissen, E., Clumeck, N., et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coninfection. Hepatology 43 (2006), 1317–1325.
12. Couinaud, C., Liver anatomy: portal (and suprahepatic) or biliary segmentation. Dig. Surg. 16 (1999), 459–467.
13. Ekstedt, M., Franzen, L.E., Mathiesen, U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006), 865–873.
14. Boyce, C.J., Pickhardt, P.J., Kim, D.H., et al. Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. AJR Am. J. Roentgenol. 194 (2010), 623–628.
15. Zeb, I., Li, D., Nasir, K., Katz, R., et al, Computed tomography scans in the evaluation of fatty liver disease in a population based study: the multi-ethnic study of atherosclerosis. Acad. Radiol. 19 (2012), 811–818.
16. Browning, J.D., Szczepaniak, L.S., Dobbins, R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004), 1387–1395.
17. Azzalini, L., Ferrer, E., Ramalho, L.N., et al. Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats. Hepatology 51 (2010), 1567–1576.
18. Hamabe, A., Uto, H., Imamura, Y., et al. Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. J. Gastroenterol. 46 (2011), 769–778.
19. Wang, Q., Du, J., Yu, P., et al. Hepatic steatosis depresses alpha-1- antitrypsin levels in human and rat acute pancreatitis. Sci. Rep., 5, 2015, 17833.
20. Janciauskiene, S.M., Bals, R., Koczulla, R., et al. The discovery of α1-antitrypsin and its role in health and disease. Respir. Med. 105 (2011), 1129–1139.
21. Cruz, M.A., Cruz, J.F., Macena, L.B., et al. Association of the nonalcoholic hepatic steatosis and its degrees with the values of liver enzymes and homeostasis model assessment-insulin resistance index. Gastroenterol. Res. 8 (2015), 260–264.
22. Tota-Maharaj, R., Blaha, M.J., Zeb, I., et al. Ethnic and sex differences in liver fat on cardiac computed tomography: the multi-ethnic study of atherosclerosis. Mayo Clin. Proc. 89 (2014), 493–503.
23. Birkenfeld, A.L., Shulman, G.I., Nonalcoholic fatty liver disease, hepatic insulin resistance and type 2 diabetes. Hepatology 59 (2014), 713–723.
24. Juárez-Rojas, J.G., Medina-Urrutia, A.X., Jorge-Galarza, E., et al. Fatty liver increases the association of metabolic syndrome with diabetes and atherosclerosis. Diabetes Care 36 (2013), 1726–1728.
25. Ndumele, C.E., Nasir, K., Conceiçao, R.D., et al. Hepatic steatosis, obesity and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 1927–1932.
26. Williams, C.D., Stengel, J., Asike, M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140 (2011), 124–131.
27. Browning, J.D., Horton, J.D., Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114 (2004), 147–152.